About Bluebird Bio
Bluebird Bio is a Healthcare company based in Cambridge (United States) founded in 1992, and was acquired by The Carlyle Group in February 2025. Gene therapies for severe genetic and rare diseases are developed. Bluebird Bio has raised $210.68 million across 11 funding rounds from investors including ABN AMRO, The Carlyle Group and RA Capital. Bluebird Bio has completed 1 acquisition, including Pregenen. Bluebird Bio offers products and services including Gene Therapy for Sickle Cell Disease, Gene Therapy for Beta-Thalassemia, and Gene Therapy for Cerebral Adrenoleukodystrophy. Its focus areas include Life Sciences, Genomics, Applied Genomics and Clinical Genomics. Its legal entity is bluebird bio, Inc. Its competitors include Moderna, BridgeBio and BeiGene; 3 of its 3 listed competitors have raised funding.
Company details
Bluebird Bio was founded in 1992 in Cambridge, United States, within the biotechnology sector. Gene therapies are developed by the company for severe genetic diseases and rare conditions, including Lenti-D for childhood cerebral adrenoleukodystrophy and LentiGlobin for rare hemoglobinopathies. Preclinical programs are pursued for multiple myeloma and HPV-associated cancers. Homing endonuclease and megaTAL gene-editing technologies are applied in hematology and oncology areas.
- Headquarters Cambridge, United States
- Stage Acquired
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Website bluebirdbio.com
- Social LinkedIn X Instagram YouTube
- Acquired by The Carlyle Group (Feb 2025)
- Legal Name Bluebird Bio, Inc.
- Total Equity Funding$210.68M (USD)
in 11 rounds
- InvestorsABN AMRO
& 11 more
- Investments & Acquisitions
- Acquired byThe Carlyle Group
(Feb 2025)
Products & Services of Bluebird Bio
Bluebird Bio offers a comprehensive portfolio of products and services, including Gene Therapy for Sickle Cell Disease, Gene Therapy for Beta-Thalassemia, and Gene Therapy for Cerebral Adrenoleukodystrophy.
FDA-approved one-time therapy to treat sickle cell disease genetically.
Treatment using lentiviral vectors for beta-thalassemia genetic disorder.
Gene-based approach to address cerebral adrenoleukodystrophy symptoms.
Apps and channels of Bluebird Bio
its YouTube channel Genetix Biotherapeutics has 59 subscribers.
Funding Insights of Bluebird Bio
Bluebird Bio has successfully raised a total of $210.68M across 11 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $210.68M
- Total Rounds 11
- First Round $12M
(Oct 2004)
- Investors Count 10
Latest 10 of 11 funding rounds of Bluebird Bio with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jun 2022 | Post-IPO | – | – | ||
| Sep 2021 | $75M | Post-IPO | – | – | – |
| Oct 2012 | $9.3M | Grant | – | – | – |
| Jul 2012 | $60M | Series D | – | – | |
| Jul 2012 | $60M | Series D | – | Third Rock Ventures, Arch Venture Partners | – |
| Apr 2011 | $15M | Series B | – | – | – |
| Apr 2011 | $15M | Series B | – | – | – |
| Mar 2010 | $37.5M | Series B | – | Third Rock Ventures, Easton Capital Investment Group | – |
| Jun 2007 | $9.18M | Series A | – | – | – |
| Nov 2006 | $2M | Series A | – | – | – |
12 investors in total: 12 institutional.
Investors in Bluebird Bio
Bluebird Bio has secured backing from 12 investors, including venture fund and institutional investors. Prominent investors backing the company include ABN AMRO, The Carlyle Group and RA Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Venture capital funding is provided to early-stage life science companies. | thirdrockventures.com | Boston, United States | ||
Venture capital firm focused on life science companies | 1986 | archventure.com | Chicago, United States | |
Capital is invested in life science innovations for healthcare transformation. | tvm-capital.com | Munich, Germany | ||
Venture capital firm focused on lifescience and healthcare sectors | forbion.com | Naarden, Netherlands | ||
| eastoncapital.com | ||||
Life-Sciences focused Early stage Corporate VC Firm investing in the US | sanofiventures.com | Paris, France | ||
A global private investment firm focused on specialty sectors. | skcapitalpartners.com | New York, United States | ||
Private equity investments are directed toward multiple sectors. | 1986 | carlyle.com | ||
RA Capital is engaged in evidence-based investing in healthcare and life sciences. | 2004 | racap.com | Boston, United States |
Investor details for Bluebird Bio
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Bluebird Bio
115 people are tracked at Bluebird Bio (66 in leadership, 3 in board & advisors, 46 in team).
| Name | Role | Group |
|---|---|---|
Tom Klima | Chief Commercial & Operating Officer | Leadership |
Paul Boutchia | Associate Director, Facilities Services & Amenities | Leadership |
Sarah Gonzalez | Vice President, Sales | Leadership |
Heidi Elliot | Director, Clinical Science | Leadership |
Adrian Chaisson | Chief Of Staff | Leadership |
Carly Duvall | Director, Commercial Operations | Leadership |
Kyle Stoddard | Associate Director Quality Assurance Operations | Leadership |
Kate Bartoces | Sales Director | Leadership |
Joe Vittiglio | Chief Business & Legal Officer | Leadership |
Sharon Schall | Senior Director QTC Engagement, Florida | Leadership |
Ellen Forest | Chief People Officer | Leadership |
John Miles | VP Commercial, Head Of Field | Leadership |
Yael Wexler-Cohen | Director | Leadership |
Lin Pan | Head Of Statistics | Leadership |
Lesley C. | Senior Director, CMC Lead Of Sickle Cell Disease Program | Leadership |
Tyson Fetzer | Vice President, Manufacturing And Supply Chain Operations | Leadership |
Hancheng Jiang | Associate Director, Biostatistics | Leadership |
Theresa Chera | Head Of Patient Supply | Leadership |
Heather Caouette | Director, CTO Engagement, Quality Control | Leadership |
Julie Batal | Vice President, Regulatory Science | Leadership |
95 more people are available in the full profile.
Complete people profiles for Bluebird Bio
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Bluebird Bio
Bluebird Bio has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Pregenen.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Limited information available | pregenen.com | Seattle, United States | 2006 | Jun 2014 | $139.9M |
Complete acquisition details for Bluebird Bio
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Bluebird Bio
6 dated milestones of Bluebird Bio across 33 years, from founding to its latest funding, stage changes and deals.
- Founded Bluebird Bio is founded.
- Funding First funding round of $12.0M.
- IPO Lists on the stock exchange (IPO).
- Acquisition Acquires Pregenen.
- Funding Latest funding round, Post-IPO,.
- Exit Acquired by The Carlyle Group.
Competitors of Bluebird Bio
Bluebird Bio has 3 listed competitors in our database, 3 of them funded. They include Moderna, BridgeBio and BeiGene.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| modernatx.com | 2010 | Cambridge, United States | $2.78B | 1,312 | mRNA-based therapeutics for diseases including cancer and infections are developed. | |
| bridgebio.com | 2015 | Palo Alto, United States | $434.2M | Therapeutics for genetic diseases are developed through targeted interventions. | ||
| beigene.com | 2010 | Cambridge, United States | $172M | 1,090 | Targeted and immune-oncology drugs for cancer treatment are developed. |
Detailed competitors of Bluebird Bio
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Bluebird Bio
The website of Bluebird Bio (bluebirdbio.com) receives about 9.1K visits a month and ranks #3,210,476 among all websites worldwide, #4,215 in Biotechnology and Pharmaceuticals.
- Monthly visits9.1K
▲ 59.4% vs previous month
- Unique visitors2.3K
per month
- Global rank#3,210,476
among all websites
- Category rank#4,215
Health · Biotechnology and Pharmaceuticals
- Bounce rate40%
- Pages per visit2.1
- Average visit31 sec
- DevicesDesktop 43% · Mobile 57%
Websites whose visitors overlap most with Bluebird Bio. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| agios.com | 100% | 21.8K | #1,284,134 | View details | |
| epizyme.com | 92% | View details | |||
| foundationmedicine.com | 84% | 65K | #611,310 | View details | |
| themedicinemaker.com | 81% | 8.1K | #2,851,127 | View details | |
| acceleronpharma.com | 79% | View details | |||
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 13 similar websites and full traffic analytics for Bluebird Bio
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 13 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Genomics & Gene Therapy Platforms
3 companies that operate in the same segment as Bluebird Bio (Genomics & Gene Therapy Platforms) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Bluebird Bio
Complete news archive for Bluebird Bio
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Bluebird Bio
Bluebird Bio was founded in 1992 and raised its 1st funding round 12 years after it was founded.
Bluebird Bio is headquartered in Cambridge, United States. It is registered at Cambridge, Massachusetts, United States.
Bluebird Bio is a funded company, having raised a total of $210.68M across 11 funding rounds to date. The company's 1st funding round was a Series A of $2M, raised on Oct 2004.
Bluebird Bio was founded in 1992 in Cambridge, United States, within the biotechnology sector. Gene therapies are developed by the company for severe genetic diseases and rare conditions, including Lenti-D for childhood cerebral adrenoleukodystrophy and LentiGlobin for rare hemoglobinopathies. Preclinical programs are pursued for multiple myeloma and HPV-associated cancers. Homing endonuclease and megaTAL gene-editing technologies are applied in hematology and oncology areas.
Bluebird Bio offers Gene Therapy for Sickle Cell Disease, Gene Therapy for Beta-Thalassemia, and Gene Therapy for Cerebral Adrenoleukodystrophy.
Bluebird Bio has made 1 acquisition, including Pregenen.
Bluebird Bio has 12 investors. Key investors include ABN AMRO, The Carlyle Group, RA Capital, Arch Venture Partners, and Tang Capital Partners.
Bluebird Bio operates through Bluebird Bio, Inc..
Yes. Bluebird Bio was acquired by The Carlyle Group in February 2025.